Home » Stocks » MRNS

Marinus Pharmaceuticals, Inc. (MRNS)

Stock Price: $13.40 USD 0.24 (1.82%)
Updated Oct 29, 2020 3:04 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 409.35M
Revenue (ttm) n/a
Net Income (ttm) -63.56M
Shares Out 30.55M
EPS (ttm) -3.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 29, 2020
Last Price $13.40
Previous Close $13.16
Change ($) 0.24
Change (%) 1.82%
Day's Open 13.14
Day's Range 12.75 - 13.49
Day's Volume 186,620
52-Week Range 4.04 - 16.28

More Stats

Market Cap 409.35M
Enterprise Value 303.46M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 30.55M
Float 27.59M
EPS (basic) -3.96
EPS (diluted) -3.87
FCF / Share -2.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.68M
Short Ratio 1.33
Short % of Float 13.33%
Beta 1.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.75
Revenue n/a
Operating Income -64.16M
Net Income -63.56M
Free Cash Flow -58.34M
Net Cash 105.90M
Net Cash / Share 3.47
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.54%
ROE -86.05%
ROIC -2,871.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 9
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$29.33*
(118.88% upside)
Low
20.0
Current: $13.40
High
35.0
Target: 29.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue-------0.10
Gross Profit-------0.10
Operating Income-54.48-37.18-19.06-28.31-24.44-11.92-5.38-1.43
Net Income-54.12-36.73-18.90-28.64-24.85-10.83-5.27-1.41
Shares Outstanding13.6310.225.894.873.731.540.120.11
Earnings Per Share-3.96-3.60-3.20-5.88-6.68-8.68-78.40-32.00
Operating Cash Flow-48.63-27.84-18.82-24.77-20.13-8.59-6.63-1.23
Capital Expenditures-0.39-0.08-0.45-0.64-0.35-0.03-0.02-0.01
Free Cash Flow-49.02-27.93-19.27-25.41-20.48-8.62-6.65-1.23
Cash & Equivalents91.6872.7353.3930.1056.2049.7210.048.63
Total Debt---5.247.367.00-2.67
Net Cash / Debt91.6872.7353.3924.8648.8342.7210.045.96
Assets98.8475.2360.6731.4559.6550.2111.828.68
Liabilities11.076.912.669.9712.739.062.3764.05
Book Value59.5768.3358.0121.4846.9241.15-60.38-55.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Marinus Pharmaceuticals, Inc.
Country United States
Employees 42
CEO Scott N. Braunstein

Stock Information

Ticker Symbol MRNS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRNS
IPO Date July 31, 2014

Description

Marinus Pharmaceuticals, a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.